- Home
- MFM vs BMEA Comparison
MFM vs BMEA Comparison
Compare MFM & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFM
- BMEA
- Stock Information
- Founded
- MFM 1986
- BMEA 2017
- Country
- MFM United States
- BMEA United States
- Employees
- MFM N/A
- BMEA N/A
- Industry
- MFM Finance Companies
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- MFM Finance
- BMEA Health Care
- Exchange
- MFM Nasdaq
- BMEA Nasdaq
- Market Cap
- MFM 231.9M
- BMEA 209.8M
- IPO Year
- MFM N/A
- BMEA 2021
- Fundamental
- Price
- MFM $5.46
- BMEA $4.06
- Analyst Decision
- MFM
- BMEA Buy
- Analyst Count
- MFM 0
- BMEA 13
- Target Price
- MFM N/A
- BMEA $37.25
- AVG Volume (30 Days)
- MFM 108.1K
- BMEA 827.4K
- Earning Date
- MFM 01-01-0001
- BMEA 10-29-2024
- Dividend Yield
- MFM 4.08%
- BMEA N/A
- EPS Growth
- MFM N/A
- BMEA N/A
- EPS
- MFM 0.03
- BMEA N/A
- Revenue
- MFM N/A
- BMEA N/A
- Revenue This Year
- MFM N/A
- BMEA N/A
- Revenue Next Year
- MFM N/A
- BMEA N/A
- P/E Ratio
- MFM $176.67
- BMEA N/A
- Revenue Growth
- MFM N/A
- BMEA N/A
- 52 Week Low
- MFM $4.37
- BMEA $3.61
- 52 Week High
- MFM $5.48
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- MFM 29.61
- BMEA 23.76
- Support Level
- MFM $5.60
- BMEA $5.55
- Resistance Level
- MFM $5.69
- BMEA $6.06
- Average True Range (ATR)
- MFM 0.06
- BMEA 0.49
- MACD
- MFM -0.02
- BMEA -0.08
- Stochastic Oscillator
- MFM 6.24
- BMEA 0.50
About MFM MFS Municipal Income Trust
MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.